ksi-101
·Code: KSI-101
ksi-101: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kodiak Sciences Inc. (KOD) | Phase 3 |
Clinical Trials (1)
A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Frequently asked questions
Who is developing ksi-101?
ksi-101 is being developed by Kodiak Sciences Inc..
How many clinical trials involve ksi-101?
BioSniper tracks 1 clinical trial involving ksi-101.
Get deeper analysis on ksi-101
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis